Check for updates

REVIEW

Is it time to scrap Scadding and adopt computed tomography for initial evaluation of sarcoidosis? [version 1; peer review: 2 approved]

Andrew Levy^{1,2}, Nabeel Hamzeh^{1,2}, Lisa A. Maier¹⁻³

¹Division of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Health, Denver, CO, USA

²Division of Pulmonary and Critical Care Sciences, Department of Medicine, University of Colorado School of Medicine, Denver, CO, USA

³Environmental and Occupational Health Department, Colorado School of Public Health, University of Colorado, Denver, CO, USA

V1 First published: 16 May 2018, 7(F1000 Faculty Rev):600
<https://doi.org/10.12688/f1000research.11068.1>

Latest published: 16 May 2018, 7(F1000 Faculty Rev):600
<https://doi.org/10.12688/f1000research.11068.1>

Abstract

In this review, we argue for the use of high-resolution computed tomography (HRCT) over chest X-ray in the initial evaluation of patients with sarcoidosis. Chest X-ray, which has long been used to classify disease severity and offer prognostication in sarcoidosis, has clear limitations compared with HRCT, including wider interobserver variability, a looser association with lung function, and poorer sensitivity to detect important lung manifestations of sarcoidosis. In addition, HRCT offers a diagnostic advantage, as it better depicts targets for biopsy, such as mediastinal/hilar lymphadenopathy and focal parenchymal disease. Newer data suggest that specific HRCT findings may be associated with important prognostic outcomes, such as increased mortality. As we elaborate in this update, we strongly recommend the use of HRCT in the initial evaluation of the patient with sarcoidosis.

Keywords

sarcoidosis, high-resolution computed tomography, chest X-ray, diagnosis

Open Peer Review

Approval Status

	1	2
version 1
16 May 2018		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Marjolein Drent**, Maastricht University, Maastricht, The Netherlands
2. **Marco Patelli**, Casa di Cura Madre Fortunata Toniolo, Bologna, Italy

Any comments on the article can be found at the end of the article.

Corresponding author: Lisa A. Maier (MaierL@NJHealth.org)

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2018 Levy A *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Levy A, Hamzeh N and Maier LA. **Is it time to scrap Scadding and adopt computed tomography for initial evaluation of sarcoidosis?** [version 1; peer review: 2 approved] F1000Research 2018, 7(F1000 Faculty Rev):600 <https://doi.org/10.12688/f1000research.11068.1>

First published: 16 May 2018, 7(F1000 Faculty Rev):600 <https://doi.org/10.12688/f1000research.11068.1>

Background

Sarcoidosis is a systemic granulomatous disease of unclear etiology that affects the lungs and thoracic lymph nodes in over 90% of patients. The disease's onset, course, and organ involvement are highly variable. Presentations can range from asymptomatic disease incidentally noted on chest imaging and acute disease with total resolution to chronic progressive disease resulting in end organ damage, such as pulmonary fibrosis, and death. In fact, chronic pulmonary disease and fibrosis are major causes of death in patients with sarcoidosis¹. The diagnosis is generally based on clinical and radiographic findings, granulomas on biopsy, and exclusion of other granulomatous diseases, such as fungal disease, tuberculosis, and chronic beryllium disease. Classically, the chest radiograph has been used for the diagnosis and prognostication of sarcoidosis in patients with suspected disease². Below, we compare the limitations and advantages of chest radiography versus computed tomography (CT) for the initial evaluation of pulmonary sarcoidosis.

Bilateral hilar lymphadenopathy is the most common finding on chest X-ray (CXR). Lung parenchymal findings are myriad, ranging from nodules and consolidations to irreversible fibrosis³. Scadding classified thoracic disease on CXR into five stages as described in Table 1⁴. Staging was derived for prognostic purposes and does not represent a natural progression of pulmonary disease in sarcoidosis. Scadding reported that as the chest radiographic stage increased, there was a lower likelihood of spontaneous remission without treatment. Over five decades later, this staging system is still used to classify patients with sarcoidosis clinically, for research studies and to provide prognostic information to patients, in part because of its simplicity⁴⁻⁶. The ubiquity, cheap cost, and low radiation of chest radiography have also contributed to the wide use of Scadding staging.

There have been no recent recommendations to help guide the use of chest imaging; as of 1999, the official American Thoracic Society guidelines recommended CXR for initial evaluation and to preserve CT scan for patients with atypical clinical or X-ray findings or for suspicion of a complication of pulmonary disease, such as bronchiectasis or fungal superinfection⁷. It is not clear whether these recommendations are still appropriate or still being followed as patients receive CT scans for many routine clinical evaluations, in the emergency room and the doctor's office.

Table 1. Scadding staging for pulmonary sarcoidosis.

Stage	Chest radiograph findings
0	No chest abnormality
I	Hilar lymphadenopathy
II	Hilar lymphadenopathy and parenchymal abnormality
III	Parenchymal abnormality without hilar lymphadenopathy
IV	Fibrosis with volume loss

Limitations of the chest radiograph

Despite past recommendations and current wide application, the use of CXR for initial evaluation and prognostication of pulmonary sarcoidosis has clear limitations. Scadding himself recognized that his staging was useful to predict prognosis in stage I and IV disease but that there was no significant difference in prognosis between stage II and III⁴. We have noted this in our clinic as well and this is due in part to the following limitations.

Impaired interobserver variability

There is significant variation in the interpretation of X-ray, even among chest radiologists. Using data from a clinical trial, Baughman *et al.* analyzed the interobserver variability between two chest radiologists comparing Scadding CXR staging at initial evaluation⁸. The authors found only fair interobserver concordance overall (weighted $\kappa = 0.43$) and fair interobserver concordance with regard to the presence of fibrosis (weighted $\kappa = 0.51$). They also noted that their chest radiologists had difficulty in agreeing on the presence of hilar lymphadenopathy and thus distinguishing stage II and III disease⁸.

Poor predictor of lung function

Chest radiography has proven to be an unreliable predictor of derangements in lung function on initial evaluation. Frequency of airflow limitation generally increases with increasing stage; however, there is significant overlap between stages and, again, no significant difference between stage II and III disease⁹. CXR staging is especially poor in predicting exercise-induced desaturation and thus oxygen levels and, in one study, offered no further prognostic value when combined with pulmonary function test parameters, such as the diffusing capacity of the lung for carbon monoxide (DLCO)¹⁰.

Missed parenchymal disease

Chest radiography has a lower sensitivity for lung parenchymal disease compared with high-resolution computed tomography (HRCT) of the chest. Multiple studies have demonstrated significant rates of parenchymal disease on HRCT in patients with either Scadding stage 0 (no disease) or Scadding stage I (nodal disease only) on initial X-ray evaluation^{11,12}. Often, patients with stage 0 or I disease have demonstrated pulmonary impairment on lung function testing, suggesting that these patients have parenchymal or airway disease that has not been captured by CXR⁹. Indeed, in our clinical experience, we have noted limited prognostic value for CXR as well as poor depiction of important parenchymal findings that are visible on corresponding HRCT, as illustrated in Figure 1. We have also noted fibrotic findings on CT that were not seen on CXR, as seen in the radiograph in Figure 2.

Advantages of high-resolution computed tomography

Based on our review and interpretation of the literature, we posit that HRCT may be a better method for the initial evaluation of patients with suspected or confirmed sarcoidosis. HRCT is able to evaluate the lungs and airways with much higher resolution than CXR, in multiple planes, and offers clinicians improved sensitivity and specificity for detecting lung abnormalities².

Figure 1. A chest radiograph and high-resolution computed tomography from the same patient are depicted. (A) The chest radiograph would be classified as stage III, as there is mild parenchymal abnormalities but no lymphadenopathy. (B) The high-resolution computed tomography demonstrates numerous nodules that track along the bronchovascular bundle bilaterally (red star), lymphadenopathy (blue arrow), and areas of ground glass opacity (white arrow).

Figure 2. A chest X-ray and high-resolution computed tomography from the same patient are depicted. (A) The chest X-ray was interpreted as Scadding stage III. (B) Computed tomography clearly demonstrates findings consistent with fibrosis, including bronchovascular distortion (blue arrow), reticulation (white arrow), and conglomerate masses (red star). These are findings that are seen in more advanced fibrotic sarcoidosis.

Classically, HRCT reveals bilateral hilar lymphadenopathy and micronodules in the lung parenchyma with a perilymphatic distribution (Figure 1). Lung findings are often more prominent in the upper lung fields. HRCT can also detect specific patterns and distribution of parenchymal and airway abnormalities

that can have clinical implications. Bronchial thickening or narrowing can be detected by HRCT and is usually predictive of granulomatous disease of the airway seen on fiberoptic survey. Extrinsic findings, such as traction bronchiectasis and bronchovascular distortion, can be detected on CT. Mosaic attenuation

seen on CT can be predictive of air trapping, an indicator of airway disease¹³.

HRCT is more sensitive in revealing fibrosis and diagnosing end-stage disease. In various studies, fibrosis has been seen in 20–50% of patients, which is much higher than the 5–10% rate estimated by using CXR on initial evaluation¹⁴. Detection of an increased frequency of fibrosis in these patients does not appear to be a trivial finding, as the presence and the pattern of fibrosis are associated with more progressive derangements in lung function, as discussed below. In addition to having a higher sensitivity of lung parenchymal findings, HRCT is better able to demonstrate lymphadenopathy and findings consistent with pulmonary hypertension, a potential complication of sarcoidosis.

Improved interobserver reliability

In one study of 80 patients with sarcoidosis, there was variable interobserver reliability ($\kappa = 0.36$ – 0.78) between chest radiologists for specific findings on HRCT, such as bronchovascular bundle thickening, reticulation, and consolidation¹¹. However, when HRCTs were evaluated using a validated semi-quantitative score of overall severity derived by Oberstein *et al.*¹², there was excellent interobserver reliability ($\kappa = 0.99$).

Association with lung function

The use of a standardized assessment of HRCT (Oberstein score) not only proved reproducible but also demonstrated a statistically significant correlation with derangements in functional parameters, such as forced expiratory volume in 1 second (FEV₁), forced vital capacity (FVC), and DLCO as well as resting and exertional arterial oxygenation¹¹. Not only is overall severity associated with decreased lung function but also specific findings on HRCT are predictive of different patterns of abnormal physiology. Abehsera *et al.* described the HRCT findings in a cohort of patients with end-stage disease and identified three distinct patterns of fibrosis in these patients: architectural distortion, linear fibrosis, and honeycombing¹⁵. Architectural distortion was associated with obstruction on pulmonary function tests, whereas honeycombing was associated with restriction and reduction in DLCO. Linear fibrosis was not associated with functional impairment¹⁵; nothing similar has been noted with Scadding stage alone.

Diagnostic and prognostic value

Sarcoidosis is increasingly diagnosed via endobronchial ultrasound (EBUS)-guided biopsy, which has increased the value of HRCT and its ability to identify the exact size and location of mediastinal and hilar lymph nodes^{16,17}. This often spares patients the morbidity of surgical biopsy. Detecting patterns of lung disease on HRCT also allows better evaluation of active versus irreversible lung disease. Oberstein *et al.* were able to detect higher inflammatory markers in both serum and bronchoalveolar lavage associated with intrapulmonary nodules and

involvement of the bronchovascular bundle¹². This may guide treatment decisions in the future, although further investigation is necessary. As noted above, HRCT has higher sensitivity in detecting fibrotic disease as compared with CXR and this may have implications for treatment or treatment response or both.

Findings on high-resolution computed tomography may also have implications for patient mortality

In a retrospective study, Walsh *et al.* derived an algorithm of independent variables that predicted mortality in patients with pulmonary sarcoidosis¹⁸. They found that two CT variables—fibrosis in 20% of lung fields and pulmonary artery diameter—as well as a composite of physiologic variables produced a staging system to predict prognosis in patients with pulmonary sarcoidosis¹⁸. Whether these results will be confirmed in other sarcoidosis groups or whether there are other uses of CT needs to be determined. Death is usually a distant occurrence in patients with sarcoidosis, so other outcomes, such as change in pulmonary function or exercise capacity, may further highlight the prognostic value of HRCT.

Conclusions

Current guidelines for the initial evaluation of sarcoidosis are stuck in the 1960s, when Scadding staging with CXR was first derived, recommending CXR for initial evaluation of patients diagnosed with sarcoidosis. We recommend HRCT of the chest during initial evaluation, as it offers better definition of lung parenchymal and airway abnormalities as well as vascular structures (which were beyond the discussion we could undertake in this article), detection of reversible versus irreversible disease, and some prediction of disease course. We recognize the risks of HRCT, including radiation and the possibility of unnecessary workup for incidental findings. For follow-up, patients with remitting or stable disease would be well served by a yearly CXR, although when there are changes in clinical course or suspicion for new complications of their underlying disease, repeat HRCT may be of use. As we further understand abnormalities in pulmonary sarcoidosis and develop new targeted treatments, HRCT and its ability to depict specific lesions and patterns may gain even greater value. With the aid of further research, it is time to come up with a new, uniform, staging system that takes into account specific CT patterns and helps prognosticate disease course, pulmonary impairment, and treatment response. Having a baseline CT for patients now may become even more important for a patient's treatment in the future and will move our current care of these patients into the 21st century.

Competing interests

The authors declare that they have no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1. **F** Swigris JJ, Olson AL, Huie TJ, *et al.*: **Sarcoidosis-related mortality in the United States from 1988 to 2007.** *Am J Respir Crit Care Med.* 2011; **183**(11): 1524–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
2. **F** Lynch JP 3rd, Ma YL, Koss MN, *et al.*: **Pulmonary sarcoidosis.** *Semin Respir Crit Care Med.* 2007; **28**(1): 53–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
3. **F** Nishino M, Lee KS, Itoh H, *et al.*: **The spectrum of pulmonary sarcoidosis: variations of high-resolution CT findings and clues for specific diagnosis.** *Eur J Radiol.* 2010; **73**(1): 66–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
4. SCADDING JG: **Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation.** *Br Med J.* 1961; **2**(5261): 1165–72.
[PubMed Abstract](#) | [Free Full Text](#)
5. Hamzeh N, Voelker A, Forssén A, *et al.*: **Efficacy of mycophenolate mofetil in sarcoidosis.** *Respir Med.* 2014; **108**(11): 1663–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Moller DR, Koth LL, Maier LA, *et al.*: **Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) Study. Sarcoidosis Protocol.** *Ann Am Thorac Soc.* 2015; **12**(10): 1561–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. **Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.** *Am J Respir Crit Care Med.* 1999; **160**(2): 736–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. **F** Baughman RP, Shipley R, Desai S, *et al.*: **Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation.** *Chest.* 2009; **136**(2): 526–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
9. Harrison BD, Shaylor JM, Stokes TC, *et al.*: **Airflow limitation in sarcoidosis—a study of pulmonary function in 107 patients with newly diagnosed disease.** *Respir Med.* 1991; **85**(1): 59–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. **F** Barros WG, Neder JA, Pereira CA, *et al.*: **Clinical, radiographic and functional predictors of pulmonary gas exchange impairment at moderate exercise in patients with sarcoidosis.** *Respiration.* 2004; **71**(4): 367–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
11. **F** Drent M, de Vries J, Lenters M, *et al.*: **Sarcoidosis: assessment of disease severity using HRCT.** *Eur Radiol.* 2003; **13**(11): 2462–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
12. Oberstein A, von Zitzewitz H, Schweden F, *et al.*: **Non invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography.** *Sarcoidosis Vasc Diffuse Lung Dis.* 1997; **14**(1): 65–72.
[PubMed Abstract](#)
13. Lenique F, Brauner MW, Grenier P, *et al.*: **CT assessment of bronchi in sarcoidosis: endoscopic and pathologic correlations.** *Radiology.* 1995; **194**(2): 419–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. **F** Nunes H, Uzunhan Y, Gille T, *et al.*: **Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function.** *Eur Respir J.* 2012; **40**(3): 750–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
15. **F** Abehsera M, Valeyre D, Grenier P, *et al.*: **Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function.** *AJR Am J Roentgenol.* 2000; **174**(6): 1751–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
16. **F** de Boer S, Milne DG, Zeng I, *et al.*: **Does CT scanning predict the likelihood of a positive transbronchial biopsy in sarcoidosis?** *Thorax.* 2009; **64**(5): 436–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
17. **F** Eckardt J, Olsen KE, Jørgensen OD, *et al.*: **Minimally invasive diagnosis of sarcoidosis by EBUS when conventional diagnostics fail.** *Sarcoidosis Vasc Diffuse Lung Dis.* 2010; **27**(1): 43–8.
[PubMed Abstract](#) | **F1000 Recommendation**
18. **F** Walsh SL, Wells AU, Sverzellati N, *et al.*: **An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study.** *Lancet Respir Med.* 2014; **2**(2): 123–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Marco Patelli

Casa di Cura Madre Fortunata Toniolo, Bologna, Italy

Competing Interests: No competing interests were disclosed.

2. Marjolein Drent

Department of Pharmacology and Toxicology, Faculty of Health, Medicine and Life Science, Maastricht University, Maastricht, The Netherlands

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research